Cat. No.: HY-110293

CHMFL-FLT3-122

Customer Review

Based on 1 Customer Validation

CHMFL-FLT3-122 is a potent, selective and orally active FLT3 kinase with an IC₅₀ of 40 nM. CHMFL-FLT3-122 shows selectivity for FLT3 over BTK (IC₅₀ of 421 nM) and c-KIT (IC₅₀ of 559 nM) kinases. CHMFL-FLT3-122 induces apoptosis by arresting the cell cycle into the G0/G1 phase.

For research use only. We do not sell to patients.

Purity: 98.47%
CAS No.: 1839150-56-9
Formula: C₂₆H₂₉N₇O₂
Molecular Weight:471.55

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CHMFL-FLT3-122 Chemical Structure

CAS No.: 1839150-56-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 40 nM (FLT3 kinase), 421 nM (BTK), 559 nM (c-KIT)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	GI₅₀	0.003 μM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 D835V mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of FLT3 D835V mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.004 μM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 D835H mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of FLT3 D835H mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.011 μM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 ITD mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of FLT3 ITD mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.016 μM Compound: 18; CHMFL-FLT3-122	Inhibition of wild-type FLT3 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of wild-type FLT3 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.033 μM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 D835Y mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of FLT3 D835Y mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.17 μM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3-ITD-D835Y mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of FLT3-ITD-D835Y mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.22 μM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3-ITD-F691L mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of FLT3-ITD-F691L mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.28 μM Compound: 18; CHMFL-FLT3-122	Inhibition of BMX (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of BMX (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.3 μM Compound: 18; CHMFL-FLT3-122	Inhibition of JAK2 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of JAK2 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.31 μM Compound: 18; CHMFL-FLT3-122	Inhibition of LCK (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of LCK (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.65 μM Compound: 18; CHMFL-FLT3-122	Inhibition of RET (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of RET (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.68 μM Compound: 18; CHMFL-FLT3-122	Inhibition of PDGFRB (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of PDGFRB (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.88 μM Compound: 18; CHMFL-FLT3-122	Inhibition of HCK (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of HCK (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	0.94 μM Compound: 18; CHMFL-FLT3-122	Inhibition of BLK (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of BLK (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	1.8 μM Compound: 18; CHMFL-FLT3-122	Inhibition of EGFR (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of EGFR (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	1.9 μM Compound: 18; CHMFL-FLT3-122	Inhibition of c-KIT (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of c-KIT (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	2.2 μM Compound: 18; CHMFL-FLT3-122	Inhibition of MET (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of MET (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	2.5 μM Compound: 18; CHMFL-FLT3-122	Inhibition of JAK3 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of JAK3 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	3.8 μM Compound: 18; CHMFL-FLT3-122	Inhibition of JAK1 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay Inhibition of JAK1 (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
BaF3	GI₅₀	4.9 μM Compound: 18; CHMFL-FLT3-122	Cytotoxicity against mouse BAF3 cells assessed as cell proliferation after 72 hrs by CelltiterGlo assay Cytotoxicity against mouse BAF3 cells assessed as cell proliferation after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
JVM-2	GI₅₀	2.6 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human JVM2 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human JVM2 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
MOLM-13	EC₅₀	<30 nM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 mediated Stat5 phosphorylation in human MOLM13 cells for 4 hrs by immunoblot analysis Inhibition of FLT3 mediated Stat5 phosphorylation in human MOLM13 cells for 4 hrs by immunoblot analysis	[PMID: 26630553]
MOLM-13	EC₅₀	100 nM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 autophosphorylation at Tyr589/591 residue in human MOLM13 cells for 4 hrs by immunoblot analysis Inhibition of FLT3 autophosphorylation at Tyr589/591 residue in human MOLM13 cells for 4 hrs by immunoblot analysis	[PMID: 26630553]
MOLM-13	GI₅₀	0.021 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human MOLM13 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human MOLM13 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
MOLM-13	GI₅₀	21 nM Compound: CHMFL-FLT3-122	Growth inhibition of human MOLM-13 cells incubated for 72 hrs by CCK-8 assay Growth inhibition of human MOLM-13 cells incubated for 72 hrs by CCK-8 assay	[PMID: 32659083]
MOLM-14	EC₅₀	<30 nM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 autophosphorylation at Tyr589/591 residue in human MOLM14 cells for 4 hrs by immunoblot analysis Inhibition of FLT3 autophosphorylation at Tyr589/591 residue in human MOLM14 cells for 4 hrs by immunoblot analysis	[PMID: 26630553]
MOLM-14	EC₅₀	<30 nM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 mediated Stat5 phosphorylation in human MOLM14 cells for 4 hrs by immunoblot analysis Inhibition of FLT3 mediated Stat5 phosphorylation in human MOLM14 cells for 4 hrs by immunoblot analysis	[PMID: 26630553]
MOLM-14	GI₅₀	0.042 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human MOLM14 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human MOLM14 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
MOLM-14	GI₅₀	42 nM Compound: CHMFL-FLT3-122	Growth inhibition of human MOLM-14 cells incubated for 72 hrs by CCK-8 assay Growth inhibition of human MOLM-14 cells incubated for 72 hrs by CCK-8 assay	[PMID: 32659083]
MV4-11	EC₅₀	<30 nM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 autophosphorylation at Tyr589/591 residue in human MV4-11 cells for 4 hrs by immunoblot analysis Inhibition of FLT3 autophosphorylation at Tyr589/591 residue in human MV4-11 cells for 4 hrs by immunoblot analysis	[PMID: 26630553]
MV4-11	EC₅₀	<30 nM Compound: 18; CHMFL-FLT3-122	Inhibition of FLT3 mediated Stat5 phosphorylation in human MV4-11 cells for 4 hrs by immunoblot analysis Inhibition of FLT3 mediated Stat5 phosphorylation in human MV4-11 cells for 4 hrs by immunoblot analysis	[PMID: 26630553]
MV4-11	GI₅₀	0.022 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human MV4-11 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human MV4-11 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
MV4-11	GI₅₀	22 nM Compound: CHMFL-FLT3-122	Growth inhibition of human MV4-11 cells incubated for 72 hrs by CCK-8 assay Growth inhibition of human MV4-11 cells incubated for 72 hrs by CCK-8 assay	[PMID: 32659083]
NAMALVA	GI₅₀	6.4 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human NAMALWA cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human NAMALWA cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
NB-4	GI₅₀	3.8 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human NB4 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human NB4 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
SU-DHL-2	GI₅₀	5.5 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human SU-DHL-2 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human SU-DHL-2 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
U2932	GI₅₀	1.6 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human U2932 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human U2932 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]
U-937	GI₅₀	9.7 μM Compound: 18; CHMFL-FLT3-122	Antiproliferative activity against human U937 cells after 72 hrs by CelltiterGlo assay Antiproliferative activity against human U937 cells after 72 hrs by CelltiterGlo assay	[PMID: 26630553]

In Vitro

CHMFL-FLT3-122 (compound 18) significantly inhibits the proliferation of FLT3-ITD positive acute myeloid leukemia (AML) cancer cell lines MV4-11 (GI₅₀ = 22 nM), MOLM13/14 (GI₅₀ = 21 nM/42 nM)^[1].
CHMFL-FLT3-122 (0.03-1 μM; 24 h) could arrest cell cycle progression of these cell lines into the G0/G1 phase and induction of apoptosis^[1].
CHMFL-FLT3-122 (0.03-1 μM; 24 h) significantly inhibits FLT3 auto-phosphorylation at Tyr589/591 site, and also inhibits the phosphorylation of Stat5 ERK, AKT and expression of cMYC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

MV4-11, MOML14 and MOLM13 cells
Concentration:

0.03 μM, 0.1 μM, 0.3 μM, 1 μM
Incubation Time:

24 h
Result:

Arrested cell cycle progression.

Western Blot Analysis^[1]

Cell Line:

MV4-11, MOML14 and MOLM13 cells
Concentration:

0.03 μM, 0.1 μM, 0.3 μM, 1 μM
Incubation Time:

24 h
Result:

Significantly affected FLT3 auto-phosphorylation at Tyr589/591 site.

In Vivo

CHMFL-FLT3-122 (12.5-50 mg/kg; oral gavage; once a day; for 22 days) could almost completely suppress the tumor progression, and does not significantly affect the mice body weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female nu/nu mice injected with MV4-11cells^[1]
Dosage:

12.5 mg/kg, 25 mg/kg and 50 mg/kg
Administration:

Oral gavage; once a day; for 22 days
Result:

Could almost completely suppress the tumor progression.

Chemical Information

CAS No. 1839150-56-9
Appearance Solid
Molecular Weight 471.55
Formula C₂₆H₂₉N₇O₂
Color White to off-white
SMILES

NC1=C2C(N([C@H]3CN(CCC3)C(CN(C)C)=O)N=C2C4=CC=C(OC5=CC=CC=C5)C=C4)=NC=N1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (265.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1207 mL

10.6033 mL

21.2067 mL

5 mM

0.4241 mL

2.1207 mL

4.2413 mL

10 mM

0.2121 mL

1.0603 mL

2.1207 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xixiang Li, et al. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J Med Chem. 2015 Dec 24;58(24):9625-38. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1207 mL	10.6033 mL	21.2067 mL	53.0166 mL
	5 mM	0.4241 mL	2.1207 mL	4.2413 mL	10.6033 mL
	10 mM	0.2121 mL	1.0603 mL	2.1207 mL	5.3017 mL
	15 mM	0.1414 mL	0.7069 mL	1.4138 mL	3.5344 mL
	20 mM	0.1060 mL	0.5302 mL	1.0603 mL	2.6508 mL
	25 mM	0.0848 mL	0.4241 mL	0.8483 mL	2.1207 mL
	30 mM	0.0707 mL	0.3534 mL	0.7069 mL	1.7672 mL
	40 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3254 mL
	50 mM	0.0424 mL	0.2121 mL	0.4241 mL	1.0603 mL
	60 mM	0.0353 mL	0.1767 mL	0.3534 mL	0.8836 mL
	80 mM	0.0265 mL	0.1325 mL	0.2651 mL	0.6627 mL
	100 mM	0.0212 mL	0.1060 mL	0.2121 mL	0.5302 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CHMFL-FLT3-122

Apoptosis Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CHMFL-FLT3-122

Apoptosis Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CHMFL-FLT3-122 Related Classifications

Cat. No.: HY-110293